BeiGene, Ltd. (NASDAQ:BGNE) Shares Purchased by Barings LLC

Barings LLC grew its holdings in BeiGene, Ltd. (NASDAQ:BGNE) by 66.4% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 51,763 shares of the company’s stock after buying an additional 20,663 shares during the quarter. Barings LLC’s holdings in BeiGene were worth $7,385,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Headlands Technologies LLC purchased a new position in BeiGene in the 1st quarter valued at approximately $50,000. Benjamin F. Edwards & Company Inc. increased its position in shares of BeiGene by 51.5% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock valued at $128,000 after buying an additional 279 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of BeiGene during the 4th quarter worth $183,000. Acadian Asset Management LLC grew its stake in BeiGene by 204.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock valued at $197,000 after acquiring an additional 849 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. purchased a new position in BeiGene during the 1st quarter valued at about $209,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Insider Activity

In other BeiGene news, insider Titus B. Ball sold 137 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total value of $26,021.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, COO Xiaobin Wu sold 1,459 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $159.79, for a total transaction of $233,133.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Titus B. Ball sold 137 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total transaction of $26,021.78. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,210 shares of company stock worth $2,269,721. 7.43% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BGNE shares. Citigroup increased their price target on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. JPMorgan Chase & Co. increased their price objective on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Finally, Bank of America cut their target price on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research note on Tuesday, July 9th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, BeiGene presently has a consensus rating of “Moderate Buy” and a consensus price target of $237.07.

BeiGene Price Performance

BGNE opened at $211.15 on Thursday. BeiGene, Ltd. has a 1 year low of $126.97 and a 1 year high of $215.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98. The company’s 50 day simple moving average is $173.90 and its 200 day simple moving average is $162.68. The stock has a market capitalization of $20.49 billion, a PE ratio of -27.89 and a beta of 0.61.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.27) by $1.12. The company had revenue of $929.20 million during the quarter, compared to analysts’ expectations of $810.34 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business’s quarterly revenue was up 56.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($3.64) EPS. As a group, sell-side analysts expect that BeiGene, Ltd. will post -5.13 EPS for the current year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.